Silodosin to Facilitate Passage of Ureteral Stones: A Multi-institutional, Randomized, Double-blinded, Placebo-controlled Trial
/in Uncategorized/by CURCTreating Advanced Prostate Cancer: Focus on a Direct Mode of Androgen Deprivation
/in Uncategorized/by CURCTreatment Options and Select Best Practices for Men with Metastatic Castration-Resistant Prostate Cancer
/in Uncategorized/by CURCRadium-223 Dichloride for Metastatic Castration-resistant Prostate Cancer: The Urologist’s Perspective
/in Uncategorized/by CURCSafety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Expanded access in North America
/in Uncategorized/by CURCDr. Shore recently completed attendance at the Advanced Prostate Cancer Consensus Conference: APCCC in St. Gallen, Switzerland last week
/in Uncategorized/by CURCDr. Shore recently completed attendance at The Novel Therapeutics for Non-Muscle Invasive Bladder Cancer
/in Uncategorized/by CURCContact
Carolina Urologic Research Center
823 82nd Parkway, Suite B
Myrtle Beach, SC 29572
Phone: (843) 839-1679
Fax: (843) 286-0119
Email:
info@curcmb.com
Recent Happenings
- Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
- START Further Expands Its Global Oncology Site Network with the Addition of Carolina Urologic Research Center
- Final Version: Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy
- The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer
Our Affiliates
